, identifying three distinct subtypes of the disease and highlighting potential repurposable drug candidates.){kind=link}
A study published in Nature has provided new insights into the complex progression of Parkinson’s disease (PD), identifying three distinct subtypes of the disease and highlighting potential repurposable drug candidates. This research marks a significant advancement in the understanding of Parkinson’s disease, a neurodegenerative disorder known for its clinical variability and progression heterogeneity.
The study employed advanced machine learning and deep learning techniques to analyze over five years of clinical progression data from individuals with de novo Parkinson’s disease. The integrative analysis aimed to characterize phenotypic progression trajectories, leading to the identification of three pace subtypes of PD:
- Inching Pace (PD-I): Characterized by mild baseline severity and a slow progression rate.
- Moderate Pace (PD-M): Marked by mild baseline severity with a moderate progression rate.
- Rapid Pace (PD-R): Exhibiting the most rapid symptom progression.
Researchers found that specific cerebrospinal fluid markers, such as the P-tau/?-synuclein ratio, and brain atrophy in certain regions, could potentially serve as indicators for these subtypes. Additionally, genetic and transcriptomic analyses revealed molecular modules associated with each subtype, offering deeper insights into the disease’s underlying mechanisms. For example, the PD-R subtype was linked to driver genes including STAT3, FYN, BECN1, APOA1, NEDD4, and GATA2, as well as pathways related to neuroinflammation, oxidative stress, metabolism, PI3K/AKT signaling, and angiogenesis.
One of the study’s most promising findings is the identification of repurposable drug candidates targeting these subtype-specific molecular modules. Utilizing a network-based approach and cell line drug-gene signature data, the researchers evaluated potential treatment effects using two large-scale real-world patient databases. Metformin, a common diabetes medication, emerged as a potential candidate for ameliorating PD progression, especially for the rapid progression subtype (PD-R).
“This study is a significant step forward in understanding the clinical and pathophysiological complexity of Parkinson’s disease,” said the lead researcher. “By identifying distinct subtypes and potential drug candidates, we are paving the way for precision medicine approaches that could significantly improve patient outcomes.”
The findings underscore the importance of personalized treatment strategies in managing Parkinson’s disease. By tailoring therapies to specific subtypes, there is potential to enhance the effectiveness of interventions and slow disease progression more efficiently.